ClinicalTrials.gg
Not yet recruitingNCT07950761RSV-SHIELDUpdated Nov 20, 2026

Impact of Clesrovimab on Respiratory Pathogen Shedding in Infants: The RSV-SHIELD Trial

A Phase 4 interventional study of Clesrovimab and Placebo (0.9% Sodium Chloride) in RSV Infections, Pneumococcal Carriage and Respiratory, sponsored by University of Crete. Not yet recruiting at 1 site in Greece. Open to participants aged 0 Days to 12 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Crete · Phase 4, Interventional, and Prevention

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
0 Days to 12 Months
Sex
All
01

Study summary

RSV-SHIELD: Study Summary

RSV-SHIELD is an investigator-initiated, prospective, single-centre, single-blind, Phase IV, randomised, placebo-controlled clinical trial designed to investigate the effects of passive immunoprophylaxis with clesrovimab, a long-acting monoclonal antibody against respiratory syncytial virus (RSV), on nasopharyngeal pathogen carriage, respiratory microbial ecology, and local immune responses in infants.

The study aims to evaluate whether RSV prevention with clesrovimab influences not only RSV detection, viral load, and shedding dynamics but also the acquisition, persistence, and clearance of other respiratory viruses and bacterial pathogens. In addition, it will investigate changes in the nasopharyngeal microbiome and local inflammatory responses following immunoprophylaxis. These findings may provide novel insights into the interactions between RSV, other respiratory pathogens, and the developing respiratory microbiome, as well as the potential indirect effects of RSV immunoprophylaxis beyond the prevention of RSV-associated disease.

Approximately 162 healthy infants aged 0-12 months, born at a gestational age of at least 32 weeks, will be recruited at the Department of Paediatrics, University General Hospital of Heraklion, Crete, Greece. Eligible infants will fall within the approved age indication for clesrovimab but will not qualify for RSV monoclonal antibody prophylaxis under the current Greek National Immunisation Programme. Participants will be randomised in a 1:1 ratio to receive either a single intramuscular dose of clesrovimab (105 mg) or matching placebo (0.9% normal saline).

Participants will be followed for approximately eight months, with scheduled visits at baseline and months 1, 2, 3, and 5, an interim telephone assessment at month 4, and a final telephone follow-up at month 8. Additional visits will be conducted during episodes of acute respiratory tract infection.

Nasopharyngeal specimens will be collected longitudinally to assess RSV detection and viral load, other respiratory viruses, and bacterial colonisation, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Streptococcus pyogenes. Nasopharyngeal microbiome composition and diversity will be investigated using 16S rRNA sequencing. Nasal lining fluid will also be collected to measure clesrovimab concentrations and local inflammatory biomarkers.

The primary objectives encompass RSV detection and shedding dynamics, non-RSV respiratory pathogen carriage and acquisition, and changes in the nasopharyngeal microbiome and inflammatory environment. Secondary outcomes include the incidence and clinical characteristics of respiratory tract infections, including bronchiolitis, pneumonia, acute otitis media, and wheezing episodes, as well as healthcare utilisation and hospitalisations. Adverse events and serious adverse events will be monitored throughout the study.

By combining a randomised controlled design with longitudinal molecular, microbiological, and immunological assessments, RSV-SHIELD seeks to generate evidence on the broader biological effects of RSV monoclonal antibody prophylaxis. The findings may contribute to a better understanding of respiratory pathogen interactions in early life and inform future RSV prevention strategies.

Approximately 3,400 characters, including spaces - within your 5,000-character limit.

Read the detailed description

Background and Rationale

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections, bronchiolitis, and hospitalisation during infancy. The introduction of long-acting monoclonal antibodies has substantially advanced RSV prevention. Clesrovimab is a fully human, extended half-life monoclonal antibody targeting antigenic site IV of the RSV fusion (F) protein, providing protection against RSV-associated lower respiratory tract disease following a single intramuscular administration.

Although clinical trials have demonstrated the efficacy and safety of clesrovimab in preventing RSV-associated disease, its effects on nasopharyngeal RSV detection, viral load, and shedding remain insufficiently characterised. Furthermore, the potential indirect effects of RSV immunoprophylaxis on the carriage of other respiratory viruses and bacterial pathogens, the composition of the respiratory microbiome, and local mucosal inflammatory responses have not been systematically investigated.

RSV infection may alter the nasopharyngeal microbial environment through disruption of epithelial integrity, modulation of local immune responses, and interactions with other respiratory microorganisms. These changes may facilitate bacterial colonisation and viral or bacterial co-infections. Consequently, preventing RSV infection or reducing viral replication could potentially influence the acquisition, persistence, and clearance of other respiratory pathogens.

Clesrovimab has been demonstrated to reach the nasal mucosa, where it retains RSV-neutralising activity. This provides a biological rationale for investigating whether passive RSV immunoprophylaxis modifies the local respiratory microbial ecosystem and inflammatory environment beyond its established role in preventing RSV-associated clinical disease

Study Design and Population

RSV-SHIELD is an investigator-initiated, prospective, single-centre, single-blind, Phase IV, randomised, placebo-controlled clinical trial conducted at the Department of Paediatrics, University General Hospital of Heraklion, Medical School, University of Crete, Greece.

The study will enrol approximately 162 healthy infants aged 0-12 months, born at a gestational age of at least 32 weeks, during the RSV season. Participants will be infants who fall within the approved age indication for clesrovimab but are not eligible for RSV monoclonal antibody prophylaxis under the current Greek National Immunisation Programme.

Participants will be randomised in a 1:1 ratio to receive either a single intramuscular dose of clesrovimab 105 mg (0.7 mL) or placebo (0.7 mL of 0.9% normal saline). Randomisation will use a block randomisation scheme, stratified by age at enrolment (≤6 months and >6 months), with allocation implemented through sequentially numbered, opaque, sealed envelopes.

Parents or legally authorised representatives and laboratory personnel conducting the microbiological and molecular analyses will remain blinded to treatment allocation.

The study will not interfere with routine childhood immunisation, which will continue according to national recommendations.

Study Procedures and Follow-up

Each participant will be followed for approximately eight months following administration of the study intervention.

At enrolment (Day 0), eligibility will be confirmed, written informed consent obtained, and demographic, clinical, and medical history information collected. Participants will undergo a physical examination and receive the allocated study intervention. Infants will be observed for at least 30 minutes following administration.

Scheduled in-person follow-up visits will take place at months 1, 2, 3, and 5. Telephone follow-up assessments will be conducted at months 4 and 8.

At scheduled visits, information will be collected regarding respiratory symptoms, intercurrent infections, medication use, vaccinations, healthcare utilisation, hospitalisations, and adverse events.

Additional unscheduled visits will be arranged for infants who develop symptoms of an acute respiratory tract infection. These visits will include clinical assessment and additional respiratory specimen collection. Where feasible, further nasopharyngeal samples will be obtained on days 3-5 and 7-10 of the respiratory illness to investigate pathogen detection and shedding dynamics.

Microbiological and Molecular Assessments

Nasopharyngeal specimens will be collected at baseline and at months 1, 2, 3, and 5 to investigate RSV detection, viral load, and the presence of other respiratory pathogens.

RSV will be detected using molecular methods, including reverse transcription polymerase chain reaction (RT-PCR).

Other respiratory viruses of interest include influenza viruses, SARS-CoV-2, human metapneumovirus, parainfluenza viruses, rhinoviruses, adenoviruses, and other common respiratory viruses.

Bacterial pathogens of interest include Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae, and Streptococcus pyogenes.

Longitudinal sampling will enable comparisons between intervention groups regarding pathogen detection, acquisition of new pathogens, persistence of colonisation, and clearance over time.

Nasopharyngeal samples collected at baseline and month 5 will also undergo 16S ribosomal RNA gene sequencing to characterise the composition and diversity of the nasopharyngeal bacterial microbiome.

Nasal Mucosal Immunological Assessments

Nasal lining fluid will be collected at months 1 and 3 to measure local clesrovimab concentrations and inflammatory biomarkers. Additional nasal lining fluid samples will be collected during acute respiratory infections, where indicated by the study protocol.

These assessments will investigate the relationship between local monoclonal antibody concentrations, respiratory pathogen detection, and mucosal inflammatory responses.

The integration of microbiological, microbiome, and immunological data will enable exploration of potential mechanisms through which RSV immunoprophylaxis may influence respiratory microbial ecology during infancy.

Clinical Assessments

Clinical surveillance will be conducted throughout the follow-up period to document episodes of respiratory tract infection and associated healthcare utilisation.

Clinical outcomes of interest include bronchiolitis, pneumonia, acute otitis media, wheezing episodes, duration of fever and respiratory symptoms, medically attended respiratory infections, and hospitalisations.

These assessments will explore whether microbiological changes associated with clesrovimab administration correspond to differences in the clinical burden of respiratory infections.

Sample Size and Statistical Considerations

The planned sample size is 162 infants, with 81 participants allocated to each study group.

The sample size calculation is based on the proportion of infants with nasopharyngeal detection of Streptococcus pneumoniae during follow-up. Assuming a carriage prevalence of 40% in the placebo group and 22% in the clesrovimab group, corresponding to an absolute reduction of 18 percentage points, 81 participants per group are required to achieve 80% statistical power at a one-sided significance level of 0.05.

The primary analysis will follow the intention-to-treat principle, including all randomised participants according to their original treatment allocation.

Comparative analyses will assess differences in respiratory pathogen detection and carriage between treatment groups, together with longitudinal changes in pathogen acquisition, clearance, viral load, microbiome composition, and inflammatory biomarkers.

Safety Monitoring

Safety will be assessed throughout the study through documentation of adverse events, serious adverse events, and clinically significant medical conditions.

Potential risks include local injection-site reactions, hypersensitivity reactions, and transient discomfort associated with nasopharyngeal and nasal lining fluid sampling.

All study procedures will be conducted in accordance with Good Clinical Practice principles and applicable regulatory and ethical requirements.

Expected Scientific Contribution

RSV-SHIELD is designed to investigate the broader biological effects of RSV immunoprophylaxis beyond the prevention of clinically apparent RSV disease.

By combining randomised treatment allocation with longitudinal pathogen surveillance, microbiome profiling, and nasal mucosal immunological assessments, the study aims to determine whether RSV neutralisation influences the respiratory microbial ecosystem during infancy.

The findings may improve understanding of interactions between RSV, other respiratory viruses, bacterial colonisation, and mucosal immunity, and may provide evidence relevant to the wider impact of RSV prevention strategies on respiratory health in early life.

02

Conditions studied

  • RSV Infections
  • Pneumococcal Carriage
  • Respiratory
03

In context

Respiratory Syncytial Virus Infections

307 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

This study's planned enrollment of 162 is above the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.

Browse Respiratory Syncytial Virus Infections studies →

Lead sponsor

University of Crete is the lead sponsor of 25 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Days to 12 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Only infants who meet all of the following criteria will be eligible for enrolment in the study:

  1. Infants aged 0-12 months during the month preceding or during the RSV season who are not eligible to receive nirsevimab under the current Greek National Immunisation Programme (for example, term infants (>35 weeks' gestation) born between 31 October 2025 and 31 October 2026, and preterm infants (\<35 weeks' gestation) born between 31 October 2025 and 31 March 2026 who are younger than 12 months of age at the time of study enrolment).
  2. Infants born at term or preterm with a gestational age of ≥32 weeks.
  3. Infants must not have received an RSV monoclonal antibody or any other RSV prophylactic intervention within the six months preceding study enrolment.
  4. No maternal history of RSV vaccination during the pregnancy within the preceding six months.
  5. The parent(s) or legally authorised representative(s) must be willing and able to provide written and to comply with all study procedures and requirements.
  6. The infant is expected to be available for follow-up throughout the duration of the study, and the parent(s) or legally authorised representative(s) are expected to be reachable by telephone throughout the participant's study participation.

Exclusion criteria

Exclusion Criteria:

  • Infants meeting any of the following criteria will be excluded from participation in the study:

    1. Major congenital anomalies or known chromosomal abnormalities.
    2. Known or suspected primary or secondary immunodeficiency.
    3. Severe chronic lung disease requiring supplemental oxygen therapy.
    4. Cyanotic congenital heart disease.
    5. Known or suspected neuromuscular disease.
    6. Hospitalisation at the time of enrolment for an acute or chronic condition requiring admission to an intensive care unit.
    7. Infants who have received, or are eligible to receive, nirsevimab under the current Greek National Immunisation Programme for the relevant RSV season.*
    8. Infants younger than 6 months of age whose mothers received RSV vaccination during pregnancy.
    9. History of severe or anaphylactic reaction to clesrovimab or to any of the medicinal product.
    10. coagulation abnormalities or other bleeding disorders that, in the opinion of the investigator, constitute a to intramuscular administration.
    11. Any acute febrile illness or other acute infection at the time of enrolment that, in the opinion of the investigator, requires postponement of administration of the investigational medicinal product.
    12. Any other serious acute or chronic medical condition, clinically significant laboratory abnormality, or other condition that, in the opinion of the investigator, may increase the risk associated with study participation or administration of clesrovimab, or may interfere with compliance with the study procedures.
    13. Planned administration of another RSV monoclonal antibody during the study period.
    14. Planned participation in another interventional clinical trial during participation in the present study.
    15. Infants whose parents or legally authorised representatives are members of the study team or personnel directly involved in the conduct, monitoring, or evaluation of the study.

      • At the time of submission of the present protocol, nirsevimab is included in the Greek National Immunisation Programme for the prevention of RSV infection. Under the current programme, nirsevimab is recommended for newborn infants born during the period of increased RSV circulation (1 November to 31 March), provided that the mother did not receive RSV vaccination during pregnancy, as well as for preterm infants born at \<35 weeks' gestation outside the RSV season, at the beginning of the subsequent RSV season (November). Consequently, only infants who, although they fall within the approved age indication for clesrovimab, are not eligible to receive RSV immunoprophylaxis under the current Greek National Immunisation Programme will be enrolled in the study. This approach ensures that no infant is deprived of the established standard of preventive care.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Clesrovimab

    Infants will receive a single intramuscular dose of clesrovimab (105 mg) at enrolment.

    Drug: Clesrovimab

  • Placebo comparator
    Placebo

    Infants will receive a single intramuscular injection of placebo (0.7 mL sterile 0.9% sodium chloride) at enrolment.

    Other: Placebo (0.9% Sodium Chloride)

Interventions

  • Participants randomised to the intervention group will receive a single intramuscular injection of clesrovimab 105 mg (0.7 mL) at enrolment. Clesrovimab is a long-acting monoclonal antibody targeting the respiratory syncytial virus (RSV) fusion protein, administered for passive immunoprophylaxis against RSV infection.

  • OtherPlacebo (0.9% Sodium Chloride)

    Participants randomised to the placebo group will receive a single intramuscular injection of 0.7 mL sterile 0.9% sodium chloride solution at enrolment. The placebo will be prepared in an administration syringe matching the active intervention in appearance and volume to maintain participant and parent/legal guardian blinding.

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of clesrovimab on nasopharyngeal RSV detection and viral shedding during the RSV season.

    Proportion of infants with RSV detected in nasopharyngeal samples by RT-PCR, and among RSV positive infants to determine the duration of RSV shedding and time to RSV clearance.

    Time frame: From baseline through Month 8 (up to 8 months after intervention)

  2. To evaluate the effect of clesrovimab on the detection of non-RSV respiratory viruses and the carriage/colonisation of respiratory bacterial pathogens in the nasopharynx.

    Proportion of infants with detection of non-RSV respiratory viruses and carriage/colonisation of respiratory bacterial pathogens, acquisition of new pathogens, duration of viral detection or bacterial carriage, time to pathogen clearance, and viral or bacterial load, where available. Respiratory pathogens of interest include common respiratory viruses (e.g., SARS CoV-2, human metapneumovirus, influenza viruses, parainfluenza viruses, rhinoviruses, adenoviruses, and others) and bacterial pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Mycoplasma pneumoniae and Streptococcus pyogenes.

    Time frame: From baseline through Month 8 (up to 8 months after intervention)

  3. To evaluate the effect of clesrovimab on the composition and dynamics of the nasopharyngeal microbiome and local inflammatory response.

    Changes in the composition and diversity of the nasopharyngeal microbiome assessed by 16S rRNA sequencing, and changes in nasopharyngeal inflammatory biomarkers.

    Time frame: From baseline through Month 8 (up to 8 months after intervention)

Secondary outcomes

  1. To evaluate the effect of clesrovimab on clinical episodes of RSV and non-RSV respiratory tract infections.

    Incidence of bronchiolitis, pneumonia, acute otitis media, and wheezing episodes; duration of fever and other respiratory symptoms; frequency and duration of hospitalisations and medically attended healthcare visits.

    Time frame: From baseline through Month 8 (up to 8 months after intervention)

07

Study locations

1 site
  • Department of Paediatrics, General University Hospital of Heraklion, Crete, Greece
    Heraklion, Greece
    • Eleni Vergadi, MD, PhD · Contactpaed@pagni.gr · +306944594099
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published study results, including relevant demographic, clinical, virological, microbiological, and outcome data, may be shared upon reasonable request, in accordance with participant consent and applicable data protection regulations.

Supporting information: Study protocol, Informed consent form

Time frame: Beginning 12 months after publication of the primary study results and continuing for 5 years.

Access criteria: Qualified researchers may request access by contacting the Principal Investigator and submitting a scientifically justified research proposal. Requests will be reviewed for scientific merit and compliance with ethical and data protection requirements. Data will be shared following approval and execution of an appropriate data-sharing agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Aug 2029, 33 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 20, 2026
StartEst.
Nov 18, 2026
Primary completionEst.
Aug 31, 2029
CompletionEst.
Sep 30, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950761
Lead sponsor
University of Crete
Responsible party
Eleni Vergadi (Assistant Professor of Paediatrics, University of Crete) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 18, 2026 (estimated)
Primary completion
Aug 31, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Eleni Vergadi
Contact
eleni.vergadi@uoc.gr
+306944594099

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clesrovimab

Start the discussion